Epsilogen's core product is MOv18 IgE, the first therapeutic IgE antibody to enter the clinic, which targets folate receptor alpha (FRα) expressed on multiple solid tumours. A completed Phase I trial showed MOv18 IgE to be safe and well tolerated with initial signs of clinical activity reported in Nature Communications. The company has completed large-scale GMP manufacture of MOv18 IgE and will initiate a Phase Ib two-part dose-escalation and expansion trial in FRα-positive platinum-resistant ovarian cancer later this year. Epsilogen is also developing a broader IgE-based pipeline, including IgE bispecifics and IgE/IgG combination molecules (IgEGs). The recent financing will fund delivery of clinical proof of concept for MOv18 IgE and further development across the IgE pipeline. Epsilogen develops novel immunoglobulin E (IgE) antibodies to treat cancer, with a focus on solid tumours. Its lead candidate, MOv18 IgE, is the first therapeutic IgE antibody to enter the clinic. Data from a phase I trial showed MOv18 IgE to be safe and well tolerated with early signs of clinical activity. The company plans to establish clinical proof of concept for MOv18 IgE in a phase Ib trial in platinum-resistant ovarian cancer. Epsilogen is also advancing a proprietary IGEG antibody platform that combines elements of IgE and IgG to create molecules with enhanced functionality. The recent financing will fund the phase Ib study and continued development of the IGEG platform. Epsilogen began operations in 2017 as a King’s College London spin-out leveraging Professor Sophia Karagiannis’s IgE expertise.

Total raised

$57M

Funding rounds

2

Latest round

Series B

Latest activity

Sep 2024